These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18282808)

  • 1. Scotblood 2007: Tackling local and global issues in transfusion medicine - donor recruitment, effective use of blood, stem cell plasticity, and vCJD.
    Bessos H; Fraser R; Seghatchian J
    Transfus Apher Sci; 2008 Feb; 38(1):77-83. PubMed ID: 18282808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of variant CJD on transfusion practices in the UK.
    Boulton F
    Transfus Apher Sci; 2003 Apr; 28(2):107-16. PubMed ID: 12679113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variant Creutzfeldt-Jakob disease (vCJD). Precautionary measures against the risk of transmission of the agent of vCJD by blood transfusion.
    Wkly Epidemiol Rec; 2000 Nov; 75(47):377-9. PubMed ID: 11144617
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal use of blood and innovative approaches to stem cells, regenerative medicine and donor recruitment.
    Colligan D; McGowan N; Seghatchian J
    Transfus Apher Sci; 2014 Apr; 50(2):303-6. PubMed ID: 24642068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Oct; 91(3):221-30. PubMed ID: 16958834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japan plans blood-donor restrictions to combat vCJD.
    Fuyuno I
    Nature; 2005 Mar; 434(7031):260. PubMed ID: 15772611
    [No Abstract]   [Full Text] [Related]  

  • 7. Geographic exposure risk of variant Creutzfeldt-Jakob disease in US blood donors: a risk-ranking model to evaluate alternative donor-deferral policies.
    Yang H; Huang Y; Gregori L; Asher DM; Bui T; Forshee RA; Anderson SA
    Transfusion; 2017 Apr; 57(4):924-932. PubMed ID: 28261810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to reduce transfusion acquired vCJD.
    Wallis JP
    Transfus Med; 2011 Feb; 21(1):1-6. PubMed ID: 21070399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
    Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P
    Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of improved safety on maintaining a sufficient blood supply.
    Reynolds E; Wickenden C; Oliver A
    Transfus Clin Biol; 2001 Jun; 8(3):235-9. PubMed ID: 11499967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New variant Creutzfeldt-Jakob disease: a controversial but potential blood transfusion risk.
    Basu A
    Nepal Med Coll J; 2003 Jun; 5(1):51-2. PubMed ID: 16583978
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease: a European perspective.
    Domanović D; Lewin A; O'Leary P; Janner-Jametti T; El Dusouqui SA; Sousa AP; Zaaijer H; Roberts B; Bougard D; Prati D; Nordberg J; Erikstrup C; Janssen M; Lieshout-Krikke R; Gubbe K; O'Flaherty N; Mathy G; Chantillon AM; Lehtisalo R; Sørensen ØH; Tiberghien P; Thomas S
    Blood Transfus; 2024 Sep; 22(5):415-419. PubMed ID: 38814884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New case of transfusion-associated vCJD in the United Kingdom.
    Euro Surveill; 2006 Feb; 11(2):E060209.2. PubMed ID: 16804207
    [No Abstract]   [Full Text] [Related]  

  • 14. Transfusion-related vCJD: prevention strategies for prion transmission.
    Holland PV
    Lijec Vjesn; 2007 May; 129 Suppl 3():46. PubMed ID: 18959066
    [No Abstract]   [Full Text] [Related]  

  • 15. Scotblood 2012: transfusion/transplant medicine in the 2nd decade of the 21st century.
    Colligan D; McGowan N; Seghatchian J
    Transfus Apher Sci; 2013 Jun; 48(3):415-20. PubMed ID: 23643474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood transfusion and spread of variant Creutzfeldt-Jakob disease.
    Dietz K; Raddatz G; Wallis J; Müller N; Zerr I; Duerr HP; Lefèvre H; Seifried E; Löwer J
    Emerg Infect Dis; 2007 Jan; 13(1):89-96. PubMed ID: 17370520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scotblood 2010: key presentations of the past, present, and future of transfusion medicine to mark Scottish national blood transfusion service (SNBTS) anniversaries.
    Bessos H; Fraser R; Seghatchian J
    Transfus Apher Sci; 2011 Oct; 45(2):213-21. PubMed ID: 21840760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of vCJD on blood supply.
    Seitz R; von Auer F; Blümel J; Burger R; Buschmann A; Dietz K; Heiden M; Hitzler WE; Klamm H; Kreil T; Kretzschmar H; Nübling M; Offergeld R; Pauli G; Schottstedt V; Volkers P; Zerr I
    Biologicals; 2007 Apr; 35(2):79-97. PubMed ID: 17320412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood groups differ on donor deferral.
    Mitka M
    JAMA; 2001 Apr; 285(13):1694-5. PubMed ID: 11277807
    [No Abstract]   [Full Text] [Related]  

  • 20. SCOTBLOOD 2009: the quest for understanding vCJD; Claudia's Trachea implantation; transfusion triggers; Scottish histocompatibility and immunogenetics network; and islet cell transplantation.
    Bessos H; Fraser R; Seghatchian J
    Transfus Apher Sci; 2010 Feb; 42(1):89-95. PubMed ID: 20089457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.